Cases & Deals

  • Home
  • Practices
  • Bristol Myers Squibb participates in $75 million Series C financing of Accent Therapeutics

Share

Bristol Myers Squibb participates in $75 million Series C financing of Accent Therapeutics

January 2024

Client(s) Bristol-Myers Squibb Company

Jones Day advised Bristol Myers Squibb Company in connection with the $75 million Series C financing of Accent Therapeutics, a biopharmaceutical company developing precision cancer therapies by targeting RNA-modifying proteins (RMPs), aiming to translate innovative science into transformative treatments for cancer patients.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.